Literature DB >> 12535257

Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score.

Debora E Ellen1, Ymkje Stienstra, Margreet A Teelken, Pieter U Dijkstra, Winette T A van der Graaf, Tjip S van der Werf.   

Abstract

The purpose of this study of treated Buruli ulcer patients in Ghana was to identify and assess late sequelae of treated Buruli ulcer using a goniometer, and to develop a scoring system for functional limitations. Of 78 patients, 58% (n = 45) had a reduction in the range of motion of one or more joints: 30% (n = 23) had one or more functional limitations of the leg and 21% (n = 16) of the arm; 49% (n = 38) had a functional limitation. Of all patients with affected knees, the predicted average extent of limitation was 63%. In patients with affected ankles, limitation was 78% on average; in those with elbow involvement, this was 76% on average, and in wrists involved, 65%. All of the hands involved were markedly restricted. We propose a simplified and functional scoring system that should be tested for validation in a second patient sample, and, if properly validated and adjusted, can be used in future intervention trials.

Entities:  

Mesh:

Year:  2003        PMID: 12535257     DOI: 10.1046/j.1365-3156.2003.00976.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  14 in total

1.  Economic inequality caused by feedbacks between poverty and the dynamics of a rare tropical disease: the case of Buruli ulcer in sub-Saharan Africa.

Authors:  Andrés Garchitorena; Calistus N Ngonghala; Jean-Francois Guegan; Gaëtan Texier; Martine Bellanger; Matthew Bonds; Benjamin Roche
Journal:  Proc Biol Sci       Date:  2015-11-07       Impact factor: 5.349

2.  Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.

Authors:  Roch Christian Johnson; Emma Sáez-López; Esaï Sèdjro Anagonou; Godwin Gérard Kpoton; Adjimon Gilbert Ayelo; Ronald Sètondji Gnimavo; Franck Zinsou Mignanwande; Jean-Gabin Houezo; Ghislain Emmanuel Sopoh; Juliet Addo; Lindsay Orford; Georgios Vlasakakis; Nandita Biswas; Felix Calderon; Oscar Della Pasqua; Anna Gine-March; Zaida Herrador; Alfonso Mendoza-Losana; Gabriel Díez; Israel Cruz; Santiago Ramón-García
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

3.  Laboratory confirmation of Buruli ulcer disease in Togo, 2007-2010.

Authors:  Gisela Bretzel; Kristina Lydia Huber; Basil Kobara; Marcus Beissner; Ebekalisai Piten; Karl-Heinz Herbinger; Franz Xaver Wiedemann; Komi Amekuse; Abiba Banla Kere; Kerstin Helfrich; Erna Fleischmann; Thomas Löscher; Adolf Diefenhardt; Jörg Nitschke
Journal:  PLoS Negl Trop Dis       Date:  2011-07-19

4.  Buruli-ulcer induced disability in ghana: a study at apromase in the ashanti region.

Authors:  Pius Agbenorku; Anthony Edusei; Margaret Agbenorku; Thomas Diby; Esenam Nyador; Geoffrey Nyamuame; Paul Saunderson
Journal:  Plast Surg Int       Date:  2012-05-15

5.  Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.

Authors:  Nicole Scherr; Gerd Pluschke; Charles J Thompson; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2015-08-13

6.  Treatment Outcome of Patients with Buruli Ulcer Disease in Togo.

Authors:  Marcus Beissner; Nathalie Arens; Franz Wiedemann; Ebekalisaï Piten; Basile Kobara; Malkin Bauer; Karl-Heinz Herbinger; Kossi Badziklou; Abiba Banla Kere; Thomas Löscher; Jörg Nitschke; Gisela Bretzel
Journal:  PLoS Negl Trop Dis       Date:  2015-10-16

Review 7.  Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons.

Authors:  Claudio Piersimoni; Claudio Scarparo
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

8.  Persisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin.

Authors:  Janine de Zeeuw; Till F Omansen; Marlies Douwstra; Yves T Barogui; Chantal Agossadou; Ghislain E Sopoh; Richard O Phillips; Christian Johnson; K Mohammed Abass; Paul Saunderson; Pieter U Dijkstra; Tjip S van der Werf; Ymkje Stienstra; Ymkje Stientstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-13

9.  Proteomic analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen.

Authors:  José B Gama; Steffen Ohlmeier; Teresa G Martins; Alexandra G Fraga; Belém Sampaio-Marques; Maria A Carvalho; Fernanda Proença; Manuel T Silva; Jorge Pedrosa; Paula Ludovico
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07

10.  Differential Diagnosis of Skin Ulcers in a Mycobacterium ulcerans Endemic Area: Data from a Prospective Study in Cameroon.

Authors:  Laurence Toutous Trellu; Patrick Nkemenang; Eric Comte; Geneviève Ehounou; Paul Atangana; Didier Junior Mboua; Barbara Rusch; Earnest Njih Tabah; Jean-François Etard; Yolanda K Mueller
Journal:  PLoS Negl Trop Dis       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.